Cohort of Patients with Chronic Obstructive Pulmonary Disease FRESH-PEF73257-en Stéphane SCHUCK Cohort of Patients with Chronic Obstructive Pulmonary Disease EXACO FRESH-PEF73257-en 73257 FRESH-PEF73257 Frédéric MASURE Alexis CORTOT Stéphane SCHUCK SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE Epidemiology France Portal (PEF) ALTANA PHARMA AG ASTRAZENECA (FRANCE) BOEHRINGER INGELHEIM INTERNATIONAL GMBH GLAXOSMITHKLINE (FRANCE) PFIZER (FRANCE) null Frédéric;MASURE Alexis;CORTOT Stéphane;SCHUCK bronchitis COPD exacerbation cohort Pulmonary medicine Chronic obstructive pulmonary disease The main aims of the study are to qualitatively and quantitatively describe the exacerbations in a cohort of COPD patients at different levels of severity and to confirm the existence of a sub-group of patients defined as frequent exacerbators who experience a high number of exacerbations over time. Where applicable, to determine the threshold value (number of exacerbations) that distinguishes frequent exacerbations by assuming that 3 exacerbations per year, regardless of severity, are sufficient to class the patient as a “frequent” exacerbator. Several secondary aims will also be pursued. To identify factors associated with frequent exacerbators. To identify criteria more readily associated with exacerbation severity. To confirm the link between frequent exacerbators/accelerated decline in lung function. A validation of the VSRQ scale will be performed with the following metrics: replication; clinical validity through comparison with the St. George questionnaire; VSRQ unidimensional structure; VSRQ internal consistency; sensitivity to change; minimal important distance. null France Individuals Patients population Male Female Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Respiratory physicians (private practice or hospital: CHG, CHU) will enrol patients aged 40 and over with stage II or III COPD according to SPLF criteria (2003); smokers or ex-smokers (>15 pack-years); stable and with post-bronchodilator FEV1 lower than or equal to 80% of predicted value and FEV1/VC relationship <70%. Patients must accept and complete the self-monitoring log on a monthly basis and, at each exacerbation, can be contacted by phone every three months for 4 years. Participants shall sign a consent form. The following may not be included: patients with active tuberculosis, cancer (or who received cancer treatment in the last 3 years), diffuse bronchiectasis, cystic fibrosis, asthma (in clinical history), or any other diagnosed lung diseases (sarcoidosis, pulmonary fibrosis, pneumoconiosis, etc.). Other Exclusion criteria include exacerbation one month prior to enrolment; absence of a telephone and participation in another clinical or epidemiological study. Clinical data Participant-reported health data Health event/morbidity Quality of life/health perception Other Through independent healthcare practitioners [1000-10000[ individuals Other Observational Study Observational Study Cohort study 835 Unknown To be defined Access on specific project only